Short answer
Gilead Sciences (GILD) filed its Q2 2026 10-Q quarterly report on Aug 6, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $7.8B (up 10.2% year over year) with net income of −$10.5B.
Q2 2026 key financials · XBRL
- Revenue
- $7.8B
- +10.2% YoY · +12.1% QoQ
- Net income
- −$10.5B
- −635.5% YoY · −619.3% QoQ
- Operating margin
- -133.2%
- EPS (diluted)
- −$8.43
- −636.9% YoY · −623.6% QoQ
Source: XBRL data from the Gilead Sciences (GILD) Q2 2026 10-Q on SEC EDGAR. USD.
Gilead Sciences Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q2 revenue $7,803M, up 10% from $7,082M YoY
- Product gross margin 79.3% vs 78.7% YoY
- Best segment: HIV sales $5,693M, up 12%; Descovy $967M, up 48%
- Worst segment: Veklury sales $23M, down 81%; Cell Therapy $417M, down 14%
- Net loss $10,496M vs $1,960M income; acquisitions drove $11,183M IPR&D expense and $1,750M impairment charge
Risk Factors
- New tariff exposure: April 2026 Proclamation imposed 100% tariffs on patented pharmaceuticals and ingredients, expected in second half of 2026
- Most material update: Biktarvy selected for Medicare Maximum Fair Price determination effective 2028, potentially reducing pricing and profitability
- 340B compliance risk: Recent court decisions increase potential for False Claims Act qui tam actions, with substantial damages and penalties
- Near-term competitive risk: HIV revenue remains vulnerable to generic competition and inability to launch new HIV medicines
- Financial concentration risk: Approximately 90% of U.S. gross product sales historically came through three wholesalers and affiliates
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Gilead Sciences quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.